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Brachial artery ligation with total graft excision
is a safe and effective approach to prosthetic
arteriovenous graft infections
Andres Schanzer, MD,a Andrea L. Ciaranello, MD, MPH,b and Harry Schanzer, MD,c
Worcester and Boston, Mass; and New York, NY
Objective:While autogenous arteriovenous access is preferred, prosthetic arteriovenous grafts (AVG) are still required in
a large number of patients. Infection of AVGs occurs frequently and may cause life-threatening bleeding or sepsis.
Multiple treatment strategies have been advocated (ranging from graft preservation to excision with complex concomi-
tant reconstructions), indicating a lack of consensus on appropriate management of infected AVGs. We undertook this
study to evaluate if, in the setting of anastomotic involvement, brachial artery ligation distal to the origin of the deep
brachial artery accompanied by total graft excision (BAL) is safe and effective.
Methods:All prosthetic arteriovenous graft infections managed by a single surgeon between 1995 and 2006 were reviewed
retrospectively. Patients were identified from a computerized vascular registry, and data were obtained via patient charts
and the electronic medical record.
Results: We identified 45 AVG infections in 43 patients. Twenty-one patients (49%) demonstrated arterial anastomotic
involvement andwere treated with BAL; these form the cohort for this analysis.Mean patient age was 53.2 (SD 9.5) years.
The primary etiologies for end stage renal disease (ESRD) were hypertension (29%), HIV (24%), and diabetes (19%). An
upper arm AVG was present in 95% of patients; one (5%) had a forearm AVG. The majority of grafts were polytetra-
fluoroethylene (PTFE) (90%). Follow-up was 100% at 1 month, 86% at 3 months, and 67% at 6 months. No ischemic or
septic complications occurred in the 21 patients who underwent BAL.
Conclusion: BAL is an effective and expeditious method to deal with an infected arm AVG in frequently critically ill
patients with densely scarred wounds. In the short term, BAL appears to be well tolerated without resulting ischemic
complications. Further study with longer duration of follow-up is necessary to ascertain whether BAL results in definitive
cure, or whether patients may ultimately manifest ischemic changes and require additional intervention. (J Vasc Surg
2008;48:655-8.)In the United States, 480,000 patients were estimated
to have end stage renal disease (ESRD) in 2005, of whom
340,000 were managed with hemodialysis.1 Although the
National Kidney Foundation Dialysis Outcomes Quality
Initiative2 and the Fistula First Project3 have recommended
autogenous arteriovenous access as the preferred hemodi-
alysis method, significant numbers of ESRD patients re-
quire prosthetic arteriovenous grafts (AVG) for hemodial-
ysis access.4
Complication of AVGs are frequent,5 and infection
comprises a major source of morbidity and mortality for
this patient population. Because an AVG is a foreign body
that is repeatedly exposed to the external environment by
needle puncture, infectious complications can occur in 3%
to 35% of patients.6 Potential sequelae from these compli-
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life-threatening hemorrhage or sepsis. Numerous treat-
ment strategies have been developed to address infected
AVGs, depending on the age of the graft, the extent of
infection, the presence of anastomotic involvement, and
operator preference. The techniques most commonly de-
scribed are total graft excision with vein patching of the
arterial anastomotic site,7 subtotal graft excision with over-
sewing of a prosthetic remnant,8,9 and partial excision with
segmental bypass through an uncontaminated field.10,11
Because all of these treatment strategies maintain an
intact arterial suture line in a potentially infected field, they
create a risk for brachial artery bleeding complications.
Therefore, a method to manage an infected AVG that also
definitively controls the brachial artery is needed. The
purpose of the present study is to evaluate the safety and
efficacy of brachial artery ligation distal to the origin of the
deep brachial artery (BAL) accompanied by total graft
excision in the setting of an infected AVG involving the
arterial anastomotic site.
METHODS
All AVG infections managed by a single vascular sur-
geon in a University-associated practice between January
1995 and January 2006 were identified from a computer-
ized vascular registry and were reviewed retrospectively.
Data were abstracted from both patient charts and the
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tion and material, timing and type of operative revision, as
well as follow-up data were analyzed.
Brachial arterial involvement in AVG infection was
diagnosed by ultrasound visualization of fluid around the
arterial anastomosis and by clinical findings at the time of
surgery. A standardized procedure for BAL was followed
for all patients. Adequate preoperative arterial perfusion to
the ipsilateral hand was assessed by physical examination;
preoperative arteriography or pressure measurements were
not routinely performed. An Esmark tourniquet was ap-
plied from the hand to the upper arm in order to empty the
upper extremity of blood. A pneumatic tourniquet was
then placed on the proximal upper arm and inflated to 300
mm Hg. An incision was made overlying the graft to the
brachial artery anastomosis. The graft was completely de-
tached from the artery and the arteriotomy was over sewn
with a continuous running 5-0 Prolene suture line. All
ligations occurred distal to the origin of the deep brachial
artery. A small incision was then made over the venous
anastomosis in order to detach the graft from the outflow
vein. The vein was over sewn and the entire graft was
removed. In cases where the AVGwas densely incorporated
to the surrounding tissues, an external stripper was used to
detach it. Both wounds were left open, packed, and allowed
to heal secondarily. All patients received empiric antibiotic
therapy, or antibiotic therapy based on microbiologic data
where available, from the time of diagnosis of AVG infec-
tion until post operative day 14.
Perioperative mortality was defined as death within 30
days of the procedure. Upper extremity ischemia was as-
sessed by physical examination of motor strength, neuro-
logical function, and evaluation for subjective complaints of
hand pain either with exercise or while at rest. This research
was approved by the Institutional Review Board of the
Mount Sinai School of Medicine.
RESULTS
Patient population. During the study period, 45
AVG infections were treated in 43 patients. Of these, 22
patients with no anastomotic involvement were treated
with partial excision and segmental bypass through an
uncontaminated field. Two patients with anastomotic in-
volvement were treated with total graft excision and autog-
enous patching of the arterial anastomotic site. The remain-
ing 21 patients (49%), all of whom demonstrated arterial
anastomotic involvement by duplex ultrasound or clinical
findings were treated with BAL (Table); these 21 patients
form the focus of this study. There were six men and 15
women, with a mean age of 53.2 years (range, 32-67). The
primary etiologies for ESRD were hypertension (29%),
HIV (24%), and diabetes (19%). Follow-up was 100% at 1
month, 86% at 3 months, and 67% at 6 months. Because a
number of the patients in this cohort were referred into the
practice from outside practitioners, the total number of
patients who underwent AVG placement during the study
period was not obtainable. As a result, the infection inci-
dence rate could not be calculated.Treatment characteristics. Of the AVG infections
treated with BAL, 20 (95%) were straight upper arm bra-
chial artery to axillary vein AVGs and one (5%) was a
brachial artery to cephalic vein loop forearm AVG; all of the
AVGs were made of polytetrafluoroethylene (PTFE) ex-
cept for two (9%) which were bovine heterografts. The
mean time elapsed between original access placement and
BAL was 21.3 months (range, 1 to 60; SD 16.6). At the
time of BAL, all AVGs were documented to be functional
and patent according to either color flow duplex examina-
tion or auscultation of a bruit. Data relating to the specific
bacteriology associated with each AVG infection were not
available in this cohort of patients.
All patients required the placement of a new dialysis
access after their procedure. Initially, in the acute phase,
temporary dialysis catheters were utilized. Once the pa-
tients demonstrated normalization of their fever curves and
white blood cell counts as well as negative blood cultures
for 48 hours, tunneled dialysis catheters were placed. At
this time, repeat evaluation for long-term dialysis access
options in the contralateral extremity were pursued (ie, vein
mapping and arterial inflow assessment).
Outcomes. All 21 patients (100%) who underwent
BAL were seen and evaluated by the senior author imme-
diately after surgery and at 1 month postprocedure. None
of the patients complained of pain or coldness in the
ipsilateral hand. On physical examination, motor strength
and neurological sensation were unchanged from their
preoperative examination. All patients had completed anti-
biotic therapy at 1 month postprocedure; all demonstrated
complete resolution of infection as documented by physical
examination, absence of fever, and normalization of the
white blood cell count.
At 3 months, 18 (86%) of the patients returned for
evaluation. At 6 months, 14 (67%) of the patients returned
for follow-up. During the entire follow-up period, there
Table. Brachial artery ligation and prosthetic
arteriovenous graft excision cohort characteristics
Number (%)
Patients 21
Age (mean  SD) 53.2  9.5 y
Female gender 15 (71.4)
Cause of ESRD
Hypertension 6 (28.6)
HIV 6 (28.6)
Diabetes mellitus 4 (19.1)
Wegner’s granulomatosis 1 (4.8)
Pyelonephritis 1 (4.8)
Unknown 3 (14.3)
Arteriovenous graft characteristics
Upper arm (brachial artery-axillary vein) 20 (95.2)
Forearm (brachial artery-cephalic vein) 1 (4.8)
PTFE 19 (90.5)
Bovine heterograft 2 (9.5)
ESRD,End stage renal disease; PTFE, polytetrafluoroethylene;HIV, human
immunodeficiency virus.were no ischemic or septic complications observed in the
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patients required additional interventions directed at the
ipsilateral extremity.
DISCUSSION
Ligation of the brachial artery for the management of
infected AVGs has traditionally been reserved for situations
in which other therapies either fail or are not possi-
ble.8,12-14 To our knowledge, this technique has not been
promoted as a first-line therapy due to concern about the
potential risk for upper extremity ischemia. In this study, no
evidence of ischemia was seen in 21 patients treated with
BAL, and all patients experienced complete resolution of
their infections without need for additional interventions.
Acute traumatic ligation of the brachial artery has been
reported to be accompanied by significant morbidity, in-
cluding rates of amputation up to 26% in combat set-
tings.15 As a result, in the civilian trauma setting, direct
brachial artery repair has been advocated.16,17 However, in
this study, we report no ischemic complications following
therapeutic BAL for AVG infections. Three possible expla-
nations for this discrepancy arise. First, it is possible that the
historical ischemic complication rates are higher than cur-
rent rates and may have improved with contemporary med-
ical and surgical management. Second, outcomes following
traumatic BAL may be confounded by concurrent upper
extremity injury and therefore may not be generalizable to
patients with AVG infections. Third, patients with a func-
tioning AVG may adapt to decreased brachial artery inflow
by developing compensatory collateral circulation: 91% of
patients with a patent AVG demonstrate reversal of flow in
the radial and ulnar arteries but never manifest access-
induced ischemia (symptomatic steal syndrome).18 This
adaptive increase in collateral circulation may allow ligation
to be better tolerated in patients with chronically decreased
brachial artery inflow.
One additional report has examined the effect of BAL
for patients with a vascular access in place.14 Tan and
colleagues found that of 30 patients who underwent BAL,
three (10%) patients developed ischemia (two were success-
fully treated with bypass surgery, and one required ampu-
tation). Of note, in their series, all three of the patients who
experienced ischemic complications underwent ligation of
the brachial artery in the upper arm, proximal to the origin
of the deep brachial artery. Conversely, as in our series,
none of the patients in the Tan report who underwent BAL
at the level of the elbow went on to develop any signs or
symptoms of ischemia.
There are two primary advantages of BAL for the
routine treatment of an infected AVG with anastomotic
involvement. First, this strategy obviates the need for po-
tentially technically difficult dissection and placement of an
autogenous patch or oversew of a prosthetic remnant in a
scarred and infected field. Second, BAL definitively man-
ages the arterial anastomosis, and in doing so, avoids the
potentially devastating risks of vein patch rupture,13,19,20
persistent prosthetic remnant infection,8,12 or anastomotic
dehiscence.20A potential disadvantage associated with this treatment
strategy is the possibility of limiting options for future
ipsilateral AV access. Because many of the patients from this
cohort were referred into the practice from outside practi-
tioners and then returned to their primary access surgeon
once the acute infection resolved, we lack complete
follow-up relating to their next access site. Unfortunately,
we are therefore unable to comment definitively on future
hemodialysis access options after BAL. Anecdotally, it has
been our practice to pursue contralateral extremity options
and if none exist, we have performed several successful
proximal brachial artery to axillary vein loop AVGs.
This study is subject to the limitations inherent in its
retrospective study design, including a potential selection
bias as well as the lack of a control group. In addition,
assessment of ischemia was based on patient symptom
report and physical examination findings, rather than on
objective digital pressure measurement. Finally, this study
reports on follow-up to 6months postprocedure. Although
the pathophysiology of BAL suggests that the risk of isch-
emia will be highest in the short term, data to substantiate
this claim are not yet available; the possibility that patients
described in this series may develop ischemic symptoms in
the future persists. Despite these limitations, this series adds
support to previously reported data, suggesting both a low
complication risk and a high probability of resolution of
infection when BAL is performed distal to the deep brachial
artery for the management of AVG infection.
CONCLUSIONS
This study demonstrates that in 21 patients with an
infected AVG, BAL resulted in complete resolution of the
infection with no evidence of upper extremity ischemia. We
therefore propose that BAL with complete removal of all
prosthetic material is an effective and safe first-line therapy
for patients who present with an AVG infection involving
the brachial artery at the level of the elbow.
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